July 2026
MDMA
What July 2026's 14 new studies found, synthesized from the papers below. All MDMA research →
The synthesis
Synthesized from 14 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, then ranked by relevance.
Research published in July 2026 indicates that MDMA-assisted therapy continues to show promise for PTSD and related conditions, with preliminary evidence of significant reductions in trauma symptoms (e.g., a 38% decrease in discrimination-related trauma scores in a small sample) and potential benefits for complex PTSD and borderline personality disorder, though direct studies for these latter conditions are lacking. However, evidence is mixed regarding broader effects: naturalistic use was associated with decreased neuroticism at four weeks, but a systematic review found limited direct evidence for improved social cognition, and a preclinical study suggests noradrenergic modulation may attenuate some MDMA effects. The main caveats are small sample sizes, early-stage implementation, and the need for larger, more diverse trials to confirm durability and safety.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments 2026 | review | Supports | Australia's regulatory pathway for MDMA and psilocybin prescriptions has grown rapidly (140% increase in MDMA prescribers in six months) but remains early-stage, with authorized prescribers representing about 1% of the psychiatric workforce. | |
| Changes in trauma symptoms of discrimination after MDMA-assisted psychotherapy for posttraumatic stress disorder. 2026 | preliminary study | 5 | Supports | MDMA-assisted therapy significantly reduced discrimination-related trauma symptoms, with a 38% decrease in TSDS scores and a large effect size (Cohen's d = 1.28). |
| Dermatological manifestations associated with chemsex 2026 | review | Unclear | MDMA use in chemsex is associated with oral mucositis and painful aphthous-like ulcers due to bruxism and xerostomia, highlighting dermatological risks. | |
| Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA 2026 | clinical trial | 36 | Supports | Ketamine and MDMA induce peripheral DNA methylation changes that converge on neuroplasticity and neuroimmune pathways. |
| What are the risks of serotonin syndrome when using MDMA and SSRIs together? 2026 | review | Unclear | Combined use of MDMA and SSRIs may increase the risk of serotonin syndrome, but evidence is limited or indirect. | |
| α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice. 2026 | preclinical experimental study | Mixed | Activation of the noradrenergic alpha-2 receptor suppresses 5-HT2A-mediated head-twitch responses without blocking antidepressant-like effects, suggesting a modulatory role for noradrenergic signaling in MDMA and psilocybin effects. | |
| Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Memory Reconsolidation, Complex Systems, and the Defense Cascade 2026 | theoretical or philosophical paper | Supports | Argues that MDMA therapy durably improves many mental illnesses through the reconsolidation of inaccurate mental models, based on memory reconsolidation, predictive processing, complex systems, and the defense cascade. | |
| EFICÁCIA COMPARATIVA DE PSICODÉLICOS (PSILOCIBINA E MDMA) NO TRATAMENTO DE TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO E DEPRESSÃO RESISTENTE AO TRATAMENTO: REVISÃO SISTEMÁTICA 2026 | systematic review | 8 | Supports | Psilocybin and MDMA, administered in structured therapeutic settings, produce clinically relevant effects for treatment-resistant depression and PTSD, respectively, with MDMA-AT reducing CAPS-5 scores and 67-71% of participants no longer meeting PTSD criteria in two Phase 3 trials. |
| Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015–2019 2026 | cross-sectional analysis of nationally representative survey data | Mixed | Sexual identity moderates the associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes, with weaker or absent links among sexual minority individuals compared to heterosexual individuals. | |
| Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants. 2026 | randomized controlled trial | 24 | Supports | The 30 mg dose of 2C-B produced entactogenic and psychedelic effects similar to MDMA and psilocybin, with less cardiovascular stimulation than MDMA and less distress than psilocybin. |
| Making a case for using MDMA-assisted psychotherapy for borderline personality disorder and complex PTSD: a descriptive systematic review of the literature 2026 | descriptive systematic review | 335 | Supports | MDMA-assisted psychotherapy may have applicability beyond PTSD, with potential benefits for complex PTSD and borderline personality disorder, though no studies directly assessed these conditions. |
| Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review. 2026 | systematic review | 20 | Mixed | Psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, but direct evidence of improved social-cognitive functioning remains limited. |
| Changes in neuroticism and values after naturalistic use of psychedelics and MDMA: a prospective survey study 2026 | prospective observational study | 74 | Supports | Planned naturalistic use of psychedelics and MDMA was associated with decreased neuroticism at four weeks and transient increases in the importance of relational and spiritual values, with family values remaining elevated at four weeks. |
| MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder 2026 | randomized controlled trial | 100 | Unclear | The trial will test whether MDMA-assisted integrated exposure therapy improves PTSD and alcohol use outcomes compared to active control-assisted integrated exposure therapy in comorbid PTSD and AUD. |
Australia's regulatory pathway for MDMA and psilocybin prescriptions has grown rapidly (140% increase in MDMA prescribers in six months) but remains early-stage, with authorized prescribers representing about 1% of the psychiatric workforce.
review
MDMA-assisted therapy significantly reduced discrimination-related trauma symptoms, with a 38% decrease in TSDS scores and a large effect size (Cohen's d = 1.28).
preliminary study Sample size: 5
MDMA use in chemsex is associated with oral mucositis and painful aphthous-like ulcers due to bruxism and xerostomia, highlighting dermatological risks.
review
Ketamine and MDMA induce peripheral DNA methylation changes that converge on neuroplasticity and neuroimmune pathways.
clinical trial Sample size: 36
Combined use of MDMA and SSRIs may increase the risk of serotonin syndrome, but evidence is limited or indirect.
review
Activation of the noradrenergic alpha-2 receptor suppresses 5-HT2A-mediated head-twitch responses without blocking antidepressant-like effects, suggesting a modulatory role for noradrenergic signaling in MDMA and psilocybin effects.
preclinical experimental study
Argues that MDMA therapy durably improves many mental illnesses through the reconsolidation of inaccurate mental models, based on memory reconsolidation, predictive processing, complex systems, and the defense cascade.
theoretical or philosophical paper
Psilocybin and MDMA, administered in structured therapeutic settings, produce clinically relevant effects for treatment-resistant depression and PTSD, respectively, with MDMA-AT reducing CAPS-5 scores and 67-71% of participants no longer meeting PTSD criteria in two Phase 3 trials.
systematic review Sample size: 8
Sexual identity moderates the associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes, with weaker or absent links among sexual minority individuals compared to heterosexual individuals.
cross-sectional analysis of nationally representative survey data
The 30 mg dose of 2C-B produced entactogenic and psychedelic effects similar to MDMA and psilocybin, with less cardiovascular stimulation than MDMA and less distress than psilocybin.
randomized controlled trial Sample size: 24
MDMA-assisted psychotherapy may have applicability beyond PTSD, with potential benefits for complex PTSD and borderline personality disorder, though no studies directly assessed these conditions.
descriptive systematic review Sample size: 335
Psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, but direct evidence of improved social-cognitive functioning remains limited.
systematic review Sample size: 20
Planned naturalistic use of psychedelics and MDMA was associated with decreased neuroticism at four weeks and transient increases in the importance of relational and spiritual values, with family values remaining elevated at four weeks.
prospective observational study Sample size: 74
The trial will test whether MDMA-assisted integrated exposure therapy improves PTSD and alcohol use outcomes compared to active control-assisted integrated exposure therapy in comorbid PTSD and AUD.
randomized controlled trial Sample size: 100
Points of agreement
- MDMA-assisted therapy shows promise for PTSD and related trauma conditions, with significant reductions in trauma symptoms reported in clinical and preliminary studies.
- MDMA induces epigenetic changes and modulates neuroplasticity and neuroimmune pathways, supporting its potential therapeutic mechanisms.
- MDMA-assisted therapy may have applicability beyond PTSD, including complex PTSD and borderline personality disorder, though direct evidence is lacking.
- MDMA is associated with both therapeutic benefits and potential risks, such as serotonin syndrome when combined with SSRIs and dermatological manifestations in chemsex contexts.
Conflicts
- A systematic review found limited direct evidence for improved social cognition, while other studies report positive effects on psychosocial functioning and self-awareness.
- Preclinical findings suggest noradrenergic modulation may attenuate some MDMA effects, potentially conflicting with the idea that MDMA's full polypharmacology is necessary for therapeutic effects.
- Naturalistic use showed decreased neuroticism at four weeks but not at one week, indicating a delayed effect, while clinical trials show more immediate symptom reductions.
Gaps
- Durability of MDMA-assisted therapy effects beyond short-term follow-up is not well established.
- Most studies have small sample sizes, limiting generalizability.
- Direct studies on MDMA for complex PTSD and borderline personality disorder are lacking.
- Long-term safety and risk of serotonin syndrome with SSRIs require more investigation.
- The impact of sexual identity and other demographic factors on MDMA effects is underexplored.
- The MPATHY trial is ongoing, so results on comorbid PTSD and AUD are not yet available.